Bevacizumab biosimilar (Shanghai Henlius Biotech)

贝伐珠单抗生物类似药（上海复宏汉霖生物）

Report date: 2026/01/14 17:43:20

Base Information

Drug NameBevacizumab biosimilar (Shanghai Henlius Biotech)
Drug Alias NameRecombinant anti-VEGF humanized antibody (Shanghai Henlius Biotech)贝伐人源化单抗生物仿制药（上海复宏汉霖生物）贝伐赛珠单抗生物仿制药（上海复宏汉霖生物）贝伐珠单抗生物仿制药（上海复宏汉霖生物）贝伐单抗生物仿制药（上海复宏汉霖生物） +[8] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar
Mechanisms of ActionVascular endothelial growth factor A inhibitors
TargetsVascular endothelial growth factor A
Therapy Area/IndicationsSolid tumoursUterine Cervical NeoplasmsFallopian Tube Neoplasms +[13] 
Global Approved IndicationsCarcinoma, Non-Small-Cell LungColorectal Neoplasms
Approved Indications in ChinaCarcinoma, Non-Small-Cell LungColorectal Neoplasms
Original Approved Country/TerritoryMainland China
Original Approved Date2021/11/30
Country/TerritoryUnited StatesMainland ChinaJapan
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesShanghai Henlius Biotech Inc
China Registration ClassN/A

Develop Information

Active CompaniesAl Tiryaq Al-Khalawi Medical CompanyShanghai Henlius Biologics Co LtdEurofarma Laboratorios Sa +[5] 
Inactive CompaniesN/A
Active IndicationsSolid tumoursUterine Cervical NeoplasmsFallopian Tube Neoplasms +[13] 
Inactive IndicationsN/A

Other Information

ATC CodeL01XC07
Related LinksN/A